immatics receives €22 million final tranche of Series D fundraising
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunother…
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunother…
. - immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 - Funding secur…
immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are…
immatics biotechnologies GmbH, ein biopharmazeutisches Unternehmen mit Schwerpunkt auf der Entwicklung fortschrittlicher…
immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active agai…
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that…
immatics biotechnologies GmbH, ein biopharmazeutisches Unternehmen mit Schwerpunkt auf der klinischen Entwicklung fortsc…
. - New investment allows immatics to perform pivotal study with its lead vaccine IMA901 in patients with renal cell ca…
immatics biotechnologies GmbH today announced having completed patient recruitment in a phase II trial with its cancer v…
Die immatics biotechnologies GmbH gab heute den erfolgreichen Abschluss der Patientenrekrutierung in der Phase-II-Studi…